NCT07172919View on ClinicalTrials.gov

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

October 20, 2027

Study Completion Date

October 20, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

Sotorasib

Sotorasib will be administered orally as a tablet.

DRUG

Panitumumab

Panitumumab will be administered as an IV infusion.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY